Roseburia: low levels, butyrate and GI-MAP results

Published October 7, 2026 · Updated October 21, 2026 · 5 min read

Roseburia is a group of gut bacteria that can produce butyrate. A low Roseburia result on GI-MAP describes the amount of targeted bacterial DNA in your sample. It does not, by itself, establish a butyrate deficiency or explain your symptoms.

On this page

What is Roseburia?

Roseburia is a genus of bacteria found in the large intestine. It includes species such as R. intestinalis, R. hominis, R. faecis and R. inulinivorans. These organisms grow under anaerobic conditions, meaning without oxygen. Laboratory studies show that strains differ in the carbohydrates they can use. [1]

During fermentation, Roseburia can make butyrate, one of the short-chain fatty acids produced by intestinal microbes. It participates in a wider community: other bacteria, including Faecalibacterium prausnitzii, also produce butyrate. A bacterial count cannot describe everything that community is doing. [2]

How GI-MAP reports Roseburia spp.

GI-MAP lists Roseburia spp. in its commensal/keystone bacteria section. “Spp.” refers to multiple species within the genus. The targeted qPCR test measures DNA in stool; this entry is not a separate measurement of each Roseburia species. [3]

  • Read the value alongside the range and units printed on your own report.
  • Do not compare that number directly with a percentage from a sequencing study or a different laboratory.
  • The Roseburia entry does not measure how much butyrate is being produced or absorbed.

For example, a low genus-level result does not establish that R. inulinivorans is missing. It also cannot identify which species should be added. See our GI-MAP results guide for help reading the rest of the report.

What do low or high Roseburia levels mean?

A low result means the reported amount falls below the laboratory’s comparison range. A high result means it falls above that range. Neither label establishes a disease, a cause of bloating or a need for treatment.

Interpretation needs context: your usual diet, recent medicines, bowel habits and the reason testing was ordered. Research about differences between groups of people cannot tell you why your own number is low. An in-range result also does not rule out a digestive condition. International experts caution against inferring metabolic function or personalized treatment from microbiome composition alone. Their consensus concerns microbiome profiling broadly and distinguishes it from targeted PCR panels. [4]

A useful question for your clinician is: “Would this result change my care after considering my symptoms and other findings?” A flag alone is not a reason to start antimicrobials or a restrictive diet.

Can food or fiber increase Roseburia?

Diet can influence these bacteria, but responses depend on the food, the organism and the existing microbial community. Research on carbohydrate use does not establish one fiber that reliably corrects every low result. [1]

A useful human example comes from a randomized crossover study of 50 healthy adults. Participants ate a potato-based or refined-grain side dish daily for four weeks per condition. The potato period increased R. faecis abundance, while fecal butyrate did not significantly change. This shows why a change in bacteria and a change in a measured metabolite are different outcomes; it was not a treatment trial for people selected for low GI-MAP results. [5]

Use this evidence to discuss nutritional adequacy and food tolerance with a clinician or dietitian, rather than to select a supplement dose from the report.

Roseburia inulinivorans and the muscle-strength study

A 2026 study linked greater R. inulinivorans abundance with stronger performance on several strength tests in human cohorts. The researchers also gave the organism to antibiotic-treated mice and observed increased grip strength. The human findings were associations; the supplementation experiment was in mice. This does not establish a muscle-building treatment for people. [6]

The species-specific finding cannot be read from the combined Roseburia spp. entry on GI-MAP. That entry is not a test of muscle strength or a prescription for a probiotic.

What about a Roseburia supplement?

Before considering a product, separate three different claims: it contains a named organism, it feeds existing gut bacteria, or it supplies a metabolite such as butyrate. Those are different interventions. Evidence for one does not establish the effects of the others.

Ask what exact species or strain was studied, whether people actually took that product, and whether the outcome was symptom improvement or only a change in a laboratory measurement. A label mentioning Roseburia or citing the muscle study does not establish that a product corrects a low GI-MAP result.

Common questions

Does low Roseburia mean I have leaky gut or IBS?

No. The Roseburia value alone does not establish either condition. Persistent symptoms need a clinical assessment rather than a diagnosis inferred from this single bacterial marker.

Is a higher Roseburia result always better?

There is no universal “more is better” target for this marker. Read the laboratory flag in context and ask whether any action would improve your health, rather than aiming for the largest number.

Does GI-MAP measure Roseburia intestinalis separately?

The standard report lists Roseburia spp. as a group. Do not treat that combined result as an individual species count or compare it with a species-specific research finding.

Should I retest just to see whether Roseburia increased?

Discuss what decision another test would inform. A different number is not, by itself, evidence that symptoms or health improved. There is no retesting schedule established by the studies discussed here for an isolated low GI-MAP Roseburia result.

Sources and review

Sources checked October 21, 2026. Manufacturer material describes the test. Laboratory experiments, human diet research, expert consensus and the human/mouse muscle study have different limits.

  1. Sheridan et al.: Polysaccharide utilization and nutritional specialization in Roseburia and related bacteria (2016)
  2. Duncan et al.: Acetate utilization by butyrate-producing human gut bacteria (2002 laboratory study)
  3. Diagnostic Solutions Laboratory: GI-MAP interpretive guide, 2025 edition (manufacturer)
  4. Porcari et al.: International consensus statement on microbiome testing in clinical practice (2025)
  5. DeMartino et al.: Potato side-dish crossover trial and fecal short-chain fatty acids (2022)
  6. Martinez-Tellez et al.: Roseburia inulinivorans and muscle strength (2026)

This article has been reviewed by Madison Ordway, FDN-P. For a correction or source question, contact Gi Map Test.